目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T62875 | |||
NF-κB-IN-3 (Compound 2) 是一种 NF-κB 抑制剂 (IC50: 0.70 μM),能够用作抗肿瘤剂。 | |||
T64025 | |||
Top/HDAC-IN-2 (45b) 是 Top 和 HDAC 的双重抑制剂,能够诱导细胞凋亡,表现出显著的抗肿瘤作用。 | |||
T62970 | |||
CDK1-IN-7 是一种 CDK1 的有效抑制剂,对 CDK1/CycB 的 IC50 值为 161.2 nM。CDK1-IN-7 通过凋亡内在途径以 p53 依赖的方式诱导细胞凋亡。CDK1-IN-7 能够选择性作用于肿瘤组织,并具有潜在的抗增殖作用。CDK1-IN-7 是一种潜在的靶向抗肿瘤药物。 | |||
T73186 | |||
HPK1-IN-31 是一种具有口服活性的造血祖细胞激酶 1 (HPK1) 抑制剂,IC50值为 0.8 nM。HPK1-IN-31 具有抗肿瘤活性,在免疫治疗方面具有巨大的潜力。 | |||
T72976 | |||
TGFβRI-IN-6 是一种有效的TGFβRI 抑制剂,IC50值为 0.55 nM。TGFβRI-IN-6 具有增强抗肿瘤免疫力的潜力。 | |||
T63159 | |||
Anticancer agent 28 在体内 H22 同种异体移植小鼠中具有良好的抗肿瘤作用。Anticancer agent 28 对 K562 细胞的作用是 Oridonin 的50倍,其 IC50 值为 0.09 μM。 | |||
T63861 | |||
CCT373566 是一种有效的、具有口服活性的转录抑制因子 BCL6降解剂 (IC50: 2.2 nM)。CCT373566 在体外表现出显著的抗增殖作用,在体内能够减少肿瘤生长。 | |||
T60590 | |||
Chloropyramine 是竞争性可逆 H1 受体拮抗剂,可用于过敏性疾病的研究,例如结膜炎和支气管哮喘。Chloropyramine 表现出抗乳腺癌活性。 | |||
T63138 | |||
PRMT5-IN-16 (Compound 20) 是一种 PRMT5 抑制剂,具有抗肿瘤作用。其中 PRMT5 是一种蛋白质精氨酸甲基转移酶,是新型的与表观遗传修饰相关的抗肿瘤靶点。 | |||
T63109 | |||
Y08284 是一种选择性的、高效的、口服具有活力的 CBP bromodomain 抑制剂 (IC50: 4.21 nM)。Y08284 能够抑制前列腺癌细胞系 LNCaP、C4-2B 和 22Rv1 的增殖,并具有抗肿瘤效果。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02848 | Adiponectin Protein, Human, Recombinant (hFc) | Human | HEK293 | ||
Adiponectin (ADIPOQ), or 30 kDa adipocyte complement-related protein (Acrp30) is a protein secreted by adipose tissue, which acts to reduce insulin resistance and atherogenic damage, but it also exerts actions in other tissues. Adiponectin mediates its actions in the periphery mainly via two receptors, AdipoR1 and AdipoR2. Adiponectin influences gonadotropin release, normal pregnancy, and assisted reproduction outcomes. Adiponectin, a beneficial adipokine, represents a major link between obesity and reproduction. Higher levels of adiponectin are associated with improved menstrual function and better outcomes in assisted reproductive cycles. Unlike other adipocytokines produced by adipose tissue, adiponectin appears to have anti-inflammatory, anti-diabetic, and anti-atherogenic properties. Several clinical studies demonstrate the inverse relationship between plasma adiponectin levels and several inflammatory markers including C-reactive protein. Adiponectin attenuates inflammatory responses to multiple stimuli by modulating signaling pathways in a variety of cell types. The anti-inflammatory properties of adiponectin may be a major component of its beneficial effects on cardiovascular and metabolic disorders including atherosclerosis and insulin resistance. Additionally, it is important factor in chronic liver diseases and chronic kidney diseases. Some cancer cell types express adiponectin receptors. Thus Adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways.
|
|||||
TMPY-05556 | Adiponectin Protein, Human, Recombinant (His) | Human | Baculovirus-Insect Cells | ||
Adiponectin (ADIPOQ), or 30 kDa adipocyte complement-related protein (Acrp30) is a protein secreted by adipose tissue, which acts to reduce insulin resistance and atherogenic damage, but it also exerts actions in other tissues. Adiponectin mediates its actions in the periphery mainly via two receptors, AdipoR1 and AdipoR2. Adiponectin influences gonadotropin release, normal pregnancy, and assisted reproduction outcomes. Adiponectin, a beneficial adipokine, represents a major link between obesity and reproduction. Higher levels of adiponectin are associated with improved menstrual function and better outcomes in assisted reproductive cycles. Unlike other adipocytokines produced by adipose tissue, adiponectin appears to have anti-inflammatory, anti-diabetic, and anti-atherogenic properties. Several clinical studies demonstrate the inverse relationship between plasma adiponectin levels and several inflammatory markers including C-reactive protein. Adiponectin attenuates inflammatory responses to multiple stimuli by modulating signaling pathways in a variety of cell types. The anti-inflammatory properties of adiponectin may be a major component of its beneficial effects on cardiovascular and metabolic disorders including atherosclerosis and insulin resistance. Additionally, it is important factor in chronic liver diseases and chronic kidney diseases. Some cancer cell types express adiponectin receptors. Thus Adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways.
|
|||||
TMPK-00491 | IL-18BP Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
|
|||||
TMPK-00492 | IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated | Cynomolgus | HEK293 | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
|
|||||
TMPK-00082 | IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 | ||
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
|
|||||
TMPK-00455 | IGF1R/CD221 Protein, Human, Recombinant (His & Avi) | Human | HEK293 | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.
|
|||||
TMPK-00658 | IGF1R/CD221 Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.
|
|||||
TMPK-00456 | IGF1R/CD221 Protein, Human, Recombinant (aa 31-932, His & Avi), Biotinylated | Human | HEK293 | ||
The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase that is frequently overexpressed by tumours, and mediates proliferation and apoptosis protection. IGF signalling also influences hypoxia signalling, protease secretion, tumour cell motility and adhesion, and thus can affect the propensity for invasion and metastasis. Therefore, the IGF1R is now an attractive anti-cancer treatment target.
|
|||||
TMPY-01681 | Adiponectin Protein, Mouse, Recombinant (His) | Mouse | HEK293 | ||
Adiponectin (ADIPOQ), or 30 kDa adipocyte complement-related protein (Acrp30) is a protein secreted by adipose tissue, which acts to reduce insulin resistance and atherogenic damage, but it also exerts actions in other tissues. Adiponectin mediates its actions in the periphery mainly via two receptors, AdipoR1 and AdipoR2. Adiponectin influences gonadotropin release, normal pregnancy, and assisted reproduction outcomes. Adiponectin, a beneficial adipokine, represents a major link between obesity and reproduction. Higher levels of adiponectin are associated with improved menstrual function and better outcomes in assisted reproductive cycles. Unlike other adipocytokines produced by adipose tissue, adiponectin appears to have anti-inflammatory, anti-diabetic, and anti-atherogenic properties. Several clinical studies demonstrate the inverse relationship between plasma adiponectin levels and several inflammatory markers including C-reactive protein. Adiponectin attenuates inflammatory responses to multiple stimuli by modulating signaling pathways in a variety of cell types. The anti-inflammatory properties of adiponectin may be a major component of its beneficial effects on cardiovascular and metabolic disorders including atherosclerosis and insulin resistance. Additionally, it is important factor in chronic liver diseases and chronic kidney diseases. Some cancer cell types express adiponectin receptors. Thus Adiponectin may act on tumour cells directly by binding and activating adiponectin receptors and downstream signalling pathways.
|
|||||
TMPY-02922 | XIAP Protein, Human, Recombinant (His) | Human | E. coli | ||
E3 ubiquitin-protein ligase XIAP / BIRC4, also known as an inhibitor of apoptosis protein 3, X-linked inhibitor of apoptosis protein, and IAP-like protein, is a protein that belongs to a family of apoptotic suppressor proteins. Members of this family share a conserved motif termed, baculovirus IAP repeat, which is necessary for their anti-apoptotic function. XIAP / BIRC4 functions through binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2 and inhibits apoptosis induced by menadione, a potent inducer of free radicals, and interleukin 1-beta converting enzyme. XIAP / BIRC4 also inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. Mutations in this encoding gene are the cause of X-linked lymphoproliferative syndrome. Alternate splicing results in multiple transcript variants. Thought to be the most potent apoptosis suppressor, XIAP / BIRC4, directly binds and inhibits caspases -3, -7 and -9. Survivin, which also binds to several caspases, is up-regulated in a many tumour cell types. Defects in XIAP / BIRC4 are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2). XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
|
|||||
TMPY-01216 | XIAP Protein, Human, Recombinant (Avi) | Human | E. coli | ||
E3 ubiquitin-protein ligase XIAP / BIRC4, also known as an inhibitor of apoptosis protein 3, X-linked inhibitor of apoptosis protein, and IAP-like protein, is a protein that belongs to a family of apoptotic suppressor proteins. Members of this family share a conserved motif termed, baculovirus IAP repeat, which is necessary for their anti-apoptotic function. XIAP / BIRC4 functions through binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2 and inhibits apoptosis induced by menadione, a potent inducer of free radicals, and interleukin 1-beta converting enzyme. XIAP / BIRC4 also inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. Mutations in this encoding gene are the cause of X-linked lymphoproliferative syndrome. Alternate splicing results in multiple transcript variants. Thought to be the most potent apoptosis suppressor, XIAP / BIRC4, directly binds and inhibits caspases -3, -7 and -9. Survivin, which also binds to several caspases, is up-regulated in a many tumour cell types. Defects in XIAP / BIRC4 are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2). XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
|